The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Interim analysis of the AVETUXIRI Trial: Avelumab combined with cetuximab and irinotecan for treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC)—A proof of concept, open-label, nonrandomized phase IIa study.
 
Marc Van Den Eynde
Consulting or Advisory Role - amgen (Inst); Lilly (Inst); Merck KGaA (Inst); SERVIER (Inst)
Research Funding - Merck KGaA (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen (Inst); Roche (Inst)
 
Nicolas Huyghe
No Relationships to Disclose
 
Astrid De Cuyper
No Relationships to Disclose
 
Isabelle Sinapi
No Relationships to Disclose
 
Marie Ferrier
No Relationships to Disclose
 
Mélanie Gilet
No Relationships to Disclose
 
Aline Van Maanen
No Relationships to Disclose
 
Marie-Laure Castella
No Relationships to Disclose
 
Jerome Galon
Stock and Other Ownership Interests - HalioDx
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; Catalym; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Northwest Biotherapeutics; Roche; Sanofi
Research Funding - AstraZeneca; ImageIQ; IO Biotech; Janssen; MedImmune; Perkin Elmer
Patents, Royalties, Other Intellectual Property - Patent holder: INSERM
 
Javier Carrasco
Research Funding - AstraZeneca; Roche